leading glp-1 treatments for diabetes 2025 How Employers Can Manage Costs in Their Health Plans 2025 dominates for GLP-1 trial

Some people feel slight nausea

[DOI] [PubMed] [Google Scholar] 108.Faludi P, Brodows R, Burger J, Ivanyi T, Braun DK

M., Boyle, J

During GLP-1associated weight loss, lean-mass changes are typically adaptive and preventable , not degenerative. GLP-1 Body Composition Changes: What Clinical Trials Show About Muscle Loss Clinical trials and body-composition sub-studies of semaglutide and tirzepatide consistently demonstrate: Fat mass accounts for most weight lost during treatment. Lean mass may decrease , particularly without resistance training or adequate protein intake. In many patients, the proportion of lean mass relative to total body weight is preserved or improved , because fat loss exceeds lean loss. Key clinical insight: GLP-1/GIP therapies improve overall body composition by preferentially reducing fat massnot by causing muscle breakdown. Lean mass refers to all the non-fat tissues in the bodyprimarily skeletal muscle , but also organs, bones, connective tissue, and body waterthat support metabolism, movement, and overall physical function

The analysis was performed considering non-differential misclassification and a sensitivity of 71%, which has been previously been observed in validation studies of these diagnoses in the Danish National Patient Register [25]